Phase II Study of INCB018424 in Patients with Advanced Hematologic Malignancies.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 27 Mar 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 18 Aug 2015 Planned primary completion date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.